Plasma proteomics of differential outcome to long-term therapy in children with idiopathic pulmonary arterial hypertension

Proteomics - Clinical Applications

Volumn 6, Issue 5-6, 2012, Pages 257-267

  Yeager, Michael E ^a,b   Colvin, Kelley L ^a   Everett, Allen D ^c   Stenmark, Kurt R ^a,d,e   Ivy, D Dunbar ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b The University of Colorado Denver   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e Gates Center for Regenerative Medicine and Stem Cell Biology   (United States)

Author keywords

Inflammation; Pulmonary hypertension; Vasodilators

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE 1; CLUSTERIN; COMPLEMENT COMPONENT C4; GLYCOPROTEIN; HAPTOGLOBIN; HEMOPEXIN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROTEOME; SERUM AMYLOID A 4; SERUM AMYLOID P; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN; VITRONECTIN;

ADOLESCENT; ARTICLE; CHILD; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL GEL ELECTROPHORESIS; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL ELECTROPHORESIS; HUMAN; INFANT; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; MASS SPECTROMETRY; MONONUCLEAR PHAGOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; PULMONARY HYPERTENSION; SCHOOL CHILD;

ADOLESCENT; BLOOD PROTEINS; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INFANT; MALE; PROTEOMICS; PULMONARY ARTERY; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84863212767     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201100078     Document Type: Article

References (61)

1. Abman, S. H., Ivy, D. D., Recent progress in understanding pediatric pulmonary hypertension. Curr. Opin. Pediatr. 2011, 23, 298-304.
2. Haworth, S. G., Idiopathic pulmonary arterial hypertension in childhood. Cardiol. Rev. 2010, 18, 64-66.
3. Tuder, R. M., Abman, S. H., Braun, T., Capron, F. et al., Development and pathology of pulmonary hypertension. J. Am. Coll. Cardiol. 2009, 54(1 Suppl), S3-S9.
4. Rabinovitch, M., Pathobiology of pulmonary hypertension. Annu. Rev. Pathol. 2007, 2, 369-399.
5. Abdul-Salam, V. B., Wharton, J., Cupitt, J., Berryman, M. et al., Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension. Circulation 2010, 12, 2058-2067.
6. Zhang, J., Zhang, Y., Li, N., Liu, Z. et al., Potential diagnostic biomarkers in serum of idiopathic pulmonary arterial hypertension. Respir. Med. 2009, 103, 1801-1806.
7. Zhang, R., Zhou, L., Li, Q., Liu, J. et al., Up-regulation of two actin-associated proteins prompts pulmonary artery smooth muscle cell migration under hypoxia. Am. J. Respir. Cell Mol. Biol. 2009, 41, 467-475.
8. Yuditskaya, S., Tumblin, A., Hoehn, G. T., Wang, G. et al., Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease. Blood 2009, 113, 1122-1128.
9. Kwapiszewska, G., Wygrecka, M., Marsh, L. M., Schmitt, S. et al., Fhl-1, a new key protein in pulmonary hypertension. Circulation 2008, 118, 1183-1194.
10. Terrier, B., Tamby, M. C., Camoin, L., Guilpain, P. et al., Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2008, 177, 1128-1134.
11. Ulrich, S., Taraseviciene-Stewart, L., Huber, L. C., Speich, R. et al., Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: a cross sectional study. Respir. Res. 2008, 9, 20.
12. Meyrick, B. O., Friedman, D. B., Billheimer, D. D., Cogan, J. D. et al., Proteomics of transformed lymphocytes from a family with familial pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2008, 177, 99-107.
13. Laudi, S., Steudel, W., Jonscher, K., Schöning, W. et al., Comparison of lung proteome profiles in two rodent models of pulmonary arterial hypertension. Proteomics 2007, 7, 2469-2478.
14. Yu, M., Wang, X. X., Zhang, F. R., Shang, Y. P. et al., Proteomic analysis of the serum in patients with idiopathic pulmonary arterial hypertension. J. Zhejiang Univ. Sci. B 2007, 8, 221-227.
15. Lamé, M. W., Jones, A. D., Wilson, D. W., Segall, H. J., Monocrotaline pyrrole targets proteins with and without cysteine residues in the cytosol and membranes of human pulmonary artery endothelial cells. Proteomics 2005, 17, 4398-4413.
16. Schott, P., Singer, S. S., Kögler, H., Neddermeier, D. et al., Pressure overload and neurohumoral activation differentially affect the myocardial proteome. Proteomics 2005, 5, 1372-1381.
17. Abdul-Salam, V. B., Paul, G. A., Ali, J. O., Gibbs, S. R. et al., Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension. Proteomics 2006, 6, 2286-2294.
18. Barst, R. J., Maislin, G., Fishman, A. P., Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999, 99, 1197-1208.
19. Barst, R. J., Ertel, S. I., Beghetti, M., Ivy, D. D., Pulmonary arterial hypertension: a comparison between children and adults. Eur. Respir. J. 2011, 37, 665-677.
20. Yung, D., Widlitz, A. C., Rosenzweig, E. B., Kerstein, D. et al., Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004, 110, 660-665.
21. Barst, R. J. L., Gersony, W., Long-term vasodilator treatment improves survival in children with primary pulmonary hypertension. Cardiol. Young 1993, 3, 89.
22. van Loon, R. L., Roofthooft, M. T., Delhaas, T., van Osch-Gevers, M. et al., Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies. Am. J. Cardiol. 2010, 106, 117-124.
23. Barst, R. J., McGoon, M. D., Elliott, C. G., Foreman, A. J. et al., Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term PAH disease management. Circulation 2011, 18, 113-122.
24. Melnick, L., Barst, R. J., Rowan, C. A., Kerstein, D. et al., Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension. Am. J. Cardiol. 2010, 105, 1485-1489.
25. Tissot, C., Ivy, D. D., Beghetti, M., Medical therapy for pediatric pulmonary arterial hypertension. J. Pediatr. 2010, 157, 528-532.
26. Barst, R. J., Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest 1986, 89, 497-503.
27. Fu, Q., Bovenkamp, D. E., Van Eyk, J. E., A rapid, economical, and reproducible method for human serum delipidation and albumin and IgG removal for proteomic analysis. Methods Mol. Biol. 2007, 357, 365-371.
28. Ho, J. T., White, J. F., Grisshammer, R., Hess, S., Analysis of a G protein-coupled receptor for neurotensin by liquid chromatography-electrospray ionization-mass spectrometry. Anal. Biochem. 2008, 376, 13-24.
29. Dhingra, V., Li, Q., Allison, A. B., Stallknecht, D. E. et al., Proteomic profiling and neurodegeneration in West-Nile-virus-infected neurons. J. Biomed. Biotechnol. 2005, 2005, 271-279.
30. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
31. Tannu, N. S., Hemby, S. E., Two-dimensional fluorescence difference gel electrophoresis for comparative proteomics profiling. Nat. Protoc. 2006, 1, 1732-1742.
32. Alban, A., David, S. O., Bjorkesten, L. et al., A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003, 3, 36-44.
33. Zurawel, A., Moore, E. E., Peltz, E. D., Jordan, J. R. et al., Proteomic profiling of the mesenteric lymph after hemorrhagic shock: differential gel electrophoresis and mass spectrometry analysis. Clin. Proteomics 2011, 8, 1-14.
34. Chen, C., Boylan, M. T., Evans, C. A., Whetton, A. D. et al., Application of two-dimensional difference gel electrophoresis to studying bone marrow macrophages and their in vivo responses to ionizing radiation. J. Proteome Res. 2005, 4, 1371-1380.
35. Hunsucker, S. W., Solomon, B., Gawryluk, J., Geiger, J. D. et al., Assessment of post-mortem-induced changes to the mouse brain proteome. J. Neurochem. 2008, 105, 725-737.
36. Rosenzweig, E. B., Feinstein, J. A., Humpl, T., Ivy, D. D., Pulmonary arterial hypertension in children: diagnostic work-up and challenges. Prog. Pediatr. Cardiol. 2009, 27, 4-11.
37. King, V. L., Thompson, J., Tannock, L. R., Serum amyloid A in atherosclerosis. Curr. Opin. Lipidol. 2011, 22, 302-307.
38. Hua, S., Song, C., Geczy, C. L., Freedman, S. B. et al., A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis. Redox Rep. 2009, 14, 187-196.
39. Obici, L., Raimondi, S., Lavatelli, F., Bellotti, V. et al., Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum. 2009, 61, 1435-1440.
40. Wilson, P. G., Thompson, J. C., Webb, N. R., de Beer F. C. et al., Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner. Am. J. Pathol. 2008, 173, 1902-1910.
41. Tannock, L. R., King, V. L., Proteoglycan mediated lipoprotein retention: a mechanism of diabetic atherosclerosis. Rev. Endocr. Metab. Disord. 2008, 9, 289-300.
42. Kappelle, P. J., Bijzet, J., Hazenberg, B. P., Dullaart, R. P., Lower serum paraoxonase-1 activity is related to higher serum amyloid a levels in metabolic syndrome. Arch. Med. Res. 2011, 42, 219-225.
43. Gungor, O., Kircelli, F., Demirci, M. S., Tuncel, P. et al., Serum paraoxonase 1 activity predicts arterial stiffness in renal transplant recipients. J. Atheroscler. Thromb. 2011, 18, 901-905.
44. Kang, K. W., Chang, H. J., Kim, Y. J., Choi, B. W. et al., Cardiac magnetic resonance imaging-derived pulmonary artery distensibility index correlates with pulmonary artery stiffness and predicts functional capacity in patients with pulmonary arterial hypertension. Circ. J. 2011, 18, 2244-2251.
45. Hunter, K. S., Lee, P. F., Lanning, C. J., Ivy, D. D. et al., Pulmonary vascular input impedance is a combined measure of pulmonary vascular resistance and stiffness and predicts clinical outcomes better than pulmonary vascular resistance alone in pediatric patients with pulmonary hypertension. Am. Heart J. 2008, 155, 166-174.
46. Boesch-Saadatmandi, C., Rimbach, G., Schrader, C., Kofler, B. M. et al., Determinants of paraoxonase activity in healthy adults. Mol. Nutr. Food Res. 2010, 54, 1842-1850.
47. Tanaka, T., Ikeda, K., Yamamoto, Y., Iida, H. et al., Effects of serum amyloid a and lysophosphatidylcholine on intracellular calcium concentration in human coronary artery smooth muscle cells. Int. Heart J. 2011, 52, 185-193.
48. Yeager, M. E., Belchenko, D. D., Nguyen, C. M., Colvin, K. L. et al., Endothelin-1, the unfolded protein response, and persistent inflammation-role of pulmonary artery smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 2012, 18, 14-22.
49. Connolly, M., Marrelli, A., Blades, M., McCormick, J. et al., Acute serum amyloid A induces migration, angiogenesis, and inflammation in synovial cells in vitro and in a human rheumatoid arthritis/SCID mouse chimera model. J. Immunol. 2010, 184, 6427-6437.
50. Cathcart, E. S., Wollheim, F. A., Cohen, A. S., Plasma protein constituents of amyloid fibrils. J. Immunol. 1967, 99, 376-385.
51. Stewart, C. R., Haw, A., 3rd, Lopez, R., McDonald, T. O. et al., Serum amyloid P colocalizes with apolipoproteins in human atheroma: functional implications. J. Lipid Res. 2007, 48, 2162-2171.
52. Bharadwaj, D., Mold, C., Markham, E., Du Clos, T. W., Serum amyloid P component binds to Fc gamma receptors and opsonizes particles for phagocytosis. J. Immunol. 2001, 166, 6735-6741.
53. Pilling, D., Roife, D., Wang, M., Ronkainen, S. D. et al., Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J. Immunol. 2007, 179, 4035-4044.
54. Castaño, A. P., Lin, S. L., Surowy, T., Nowlin, B. T. et al., Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci. Transl. Med. 2009, 1, 5ra13.
55. Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M. et al., Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1994, 1, 71-81.
56. Stenmark, K. R., Frid, M. G., Yeager, M. E., Fibrocytes: potential new therapeutic targets for pulmonary hypertension? Eur. Respir. J. 2010, 36, 1232-1235.
57. Yeager, M. E., Nguyen, C. M., Belchenko, D. D., Colvin, K. L. et al., Circulating fibrocytes are increased in children and young adults with pulmonary hypertension. Eur. Respir. J. 2012, 18, 104-111.
58. Surinova, S., Schiess, R., Hüttenhain, R., Cerciello, F. et al., On the development of plasma protein biomarkers. J. Proteome Res. 2011, 10, 5-16.
59. Madsen, C. D., Sidenius, N., The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur. J. Cell. Biol. 2008, 87, 617-629.
60. Dobryszycka, W., Biological functions of haptoglobin-new pieces to an old puzzle. Eur. J. Clin. Chem. Clin. Biochem. 1997, 35, 647-654.
61. Delanghe, J. R., Langlois, M. R., Hemopexin: a review of biological aspects and the role in laboratory medicine. Clin. Chim. Acta 2001, 312, 13-23.